Standards for Reducing Risks Associated with ePMA for SACT

It is with great pleasure to announce that the BOPA Standards for Reducing Risks Associated with ePMA for SACT have been updated and can be found in the publication section of the members only section of the website.
 
These BOPA Standards for Reducing Risks Associated with Electronic Prescribing and Medicines Administration Systems (ePMA) for Systemic Anti-Cancer Therapies (SACT) outlines steps that can be considered to be best practice in reducing the risks of errors arising from the introduction and use of e-prescribing systems for SACT within organisations.
 
If you have any queries please direct them to [email protected]
 

Latest News

By BOPA Executive Committee on 16th June 2026

BOPA Fellowship Nominations 2026 are NOW OPEN!

We are pleased to announce that BOPA Fellowship Nominations have now opened for 2026. The BOPA Fellowship Scheme Policy has been updated for a clearer nomination and selection process including specific criteria for assessing…

Read article
By Pharmaceutical Press (PhP) on 15th June 2026

Exciting new project with the Pharmaceutical Press (PhP)

Expressions of interest: We are currently seeking expressions of interest to support an exciting new project with the Pharmaceutical Press (PhP). PhP is developing a new resource to support healthcare…

Read article
By BOPA Research Subcommittee on 15th June 2026

Deadline EXTENDED: Abstract Submission for #BOPA2026

Abstract Submission for the 29th Annual BOPA Conference 2026 is now OPEN   Deadline for Abstract Submission for the 29th Annual BOPA Conference 2026 has been EXTENDED! Don’t miss the…

Read article
By BOPA on 15th June 2026

The BOPA Training and Development Grant – BOPA Conference 2026

BOPA are offering (in collaboration with Gilead) 16 funded places to the BOPA 2026 Conference in London from 2-4th Oct 20265. Information can be found here – The BOPA Training and Development Grant…

Read article